The Global Postpartum Hemorrhage (PPH) Devices Market size is expected to reach $1.05 billion by 2028, rising at a market growth of 5.2% CAGR during the forecast period.
Postpartum hemorrhage (PPH) is the most prevalent type of obstetric hemorrhage and one of the primary causes of maternal mortality. Blood loss from vaginal or cesarean delivery is known as PPH. Postpartum hemorrhage is classified based on the amount of blood lost. Blood loss of less than 500 mL is considered primary PPH, while blood loss of more than 500 mL is considered secondary PPH. Modern PPH treatment devices outperform previous procedures since they are designed to treat uterine diseases and difficulties with uterine contractions. PPH devices are non-pneumatic anti-shock garments, uterine balloon tamponade, and inject prefilled injectable systems that are used as second-line intervention devices. These devices are helpful in stopping blood flow and stabilizing the patient's condition until more serious medical help arrives.
Uterine atony, a disease in which the uterus fails to contract following the birth of the baby, is the most prevalent cause of PPH. First response interventions, such as uterotonic drugs (primarily oxytocin), isotonic crystalloids, tranexamic acid, and uterine massage; and, if necessary, refractory PPH interventions, such as compressive measures (aortic compression or bimanual uterine compression), intrauterine balloon tamponade, and nonpneumatic anti shock garment (NASG). Surgical intervention (compressive sutures, artery ligation, or hysterectomy) is required if these methods fail. In 2012, the World Health Organization (WHO) issued a conditional recommendation in favor of uterine balloon tamponade (UBT) in cases when uterotonics were unavailable or ineffective in reducing bleeding.
The COVID-19 pandemic wrought havoc on people's health and the economy around the world. It has had an impact on entire economies and businesses, as well as individual careers and lives. The outbreak also led to the unfortunate demise of millions across the world. As enterprises turn their focus away from development prospects and onto implementing exceptional measures to avoid the harmful impact of the COVID-19 pandemic, the stress of maintaining revenue levels at pre-COVID levels has become the new normal.
The postpartum hemorrhage devices market is expected to rise in response to the COVID-19 outbreak. Covid-19 infection raises the risk of pregnancy complications such as postpartum hemorrhage, which helps the market grow by increasing the number of PPH patients.
The postpartum hemorrhage devices market is growing due to a rise in complications such as acute postpartum hemorrhage. The most common and dangerous complication of childbirth is obstetric hemorrhage. Postpartum hemorrhage (PPH) is traditionally described as a blood loss of more than 500 mL estimated with a vaginal delivery or more than 1000 mL estimated during a cesarean delivery. The American College of Obstetrics and Gynecology characterized this in 2017 as an accumulation of blood loss of more than 1000 mL with signs and symptoms of hypovolemia within 24 hours after the birth procedure, regardless of delivery mode.
Governments of developing countries such as India and China are investing heavily in the healthcare sector of their respective countries. In 2020, for instance, the Indian health tech business was estimated to be worth $1.9 billion. It is predicted to reach $ 5 billion by 2023, with a CGAR of 39%. The Indian digital healthcare market was worth USD 1.50 billion in 2018 and is expected to grow to USD 6.26 billion by 2024. The expansion of the healthcare business is likely to positively impact the postpartum hemorrhage devices market. Even in developed countries, such as the United States, governments are spending enormous amounts to modernize and expand the healthcare sector.
Postpartum hemorrhage is the leading cause of maternal death in the United States, accounting for about 11% of all maternal deaths. Significantly, obstetric hemorrhage is responsible for 54-93% of maternal deaths. Health care providers’ inaccurate estimation of actual blood loss at the time of birth and in the immediate postpartum period is a major cause of delayed hemorrhage response, according to studies. Underestimations of blood loss lead healthcare providers into believing that deployment of postpartum hemorrhage are not necessary, thus, limiting the use of postpartum hemorrhage devices.
Based on Product, the market is segmented into Uterine Tamponade Devices, Prefilled Injection System, and Non-Pneumatic Anti-Shock Garment. The uterine tamponade devices segment acquired the largest revenue share in the postpartum hemorrhage devices market in 2021. This is due to the device's ability to work quickly and reduce the need for risky and expensive surgical procedures. Furthermore, the device is quick responding and less intrusive, making it a safe way to manage PPH. Moreover, since the gadget kit contains few pieces, it can be installed quickly and easily, increasing its efficacy.
| Report Attribute | Details |
|---|---|
| Market size value in 2021 | USD 748.9 Million |
| Market size forecast in 2028 | USD 1.05 Billion |
| Base Year | 2021 |
| Historical Period | 2018 to 2020 |
| Forecast Period | 2022 to 2028 |
| Revenue Growth Rate | CAGR of 5.2% from 2022 to 2028 |
| Number of Pages | 118 |
| Number of Tables | 170 |
| Report coverage | Market Trends, Revenue Estimation and Forecast, Segmentation Analysis, Regional and Country Breakdown, Companies Strategic Developments, Company Profiling |
| Segments covered | Product, Region |
| Country scope | US, Canada, Mexico, Germany, UK, France, Russia, Spain, Italy, China, Japan, India, South Korea, Singapore, Malaysia, Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria |
| Growth Drivers |
|
| Restraints |
|
Based on Regions, the market is segmented into North America, Europe, Asia Pacific, and Latin America, Middle East & Africa. The Asia Pacific acquired the highest revenue share in the postpartum hemorrhage devices market in 2021. Government initiatives to reduce maternal deaths and enable access to preferred therapy for effective management throughout the third phase of labor are projected to benefit the Asia-Pacific market even more and raise the demand for PPH devices in the upcoming years. Furthermore, the region's dearth of skilled caretakers, operating skills, and blood-transfusion facilities are expected to fuel the demand for PPH treatment devices.
Free Valuable Insights: Global Postpartum Hemorrhage (PPH) Devices Market size to reach USD 1.05 Billion by 2028
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Teleflex, Inc., Becton, Dickinson and Company, Bactiguard Holding AB, Utah Medical Products, Inc., Organon & Co., Cook Medical, Inc., PATH, Obstetrx, Inc., Zoex Corporation, and 3rd Stone Design, Inc.
By Product
By Geography
The global postpartum hemorrhage (PPH) devices market size is expected to reach $1.05 billion by 2028.
Rise in complications like obstetric hemorrhage are increasing are driving the market in coming years, however, inaccuracies in measuring blood loss in obstetric hemorrhage growth of the market.
Teleflex, Inc., Becton, Dickinson and Company, Bactiguard Holding AB, Utah Medical Products, Inc., Organon & Co., Cook Medical, Inc., PATH, Obstetrx, Inc., Zoex Corporation, and 3rd Stone Design, Inc.
Yes, Covid-19 infection raises the risk of pregnancy complications such as postpartum hemorrhage, which helps the market grow by increasing the number of PPH patients.
The Non-Pneumatic Anti-Shock Garment market is showcasing a CAGR of 6% during (2022 - 2028).
The North America is the fastest growing region in the Global Postpartum Hemorrhage (PPH) Devices Market by Region in 2021.
Unique Offerings Our team of dedicated experts can provide you with attractive expansion opportunities for your business.
